Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA orders opioid makers to develop doctor education programmes

This article was originally published in SRA

Executive Summary

In an effort to tackle the epidemic of abuse and misuse of prescription opioid painkillers in the US, officials from the Food and Drug Administration, the Drug Enforcement Administration, the Departments of Veterans Affairs and Defense and the White House Office of National Drug Control Policy have laid out a multi-prong strategy which includes the details of a much-anticipated risk evaluation and mitigation strategy (REMS) requirement for makers of all extended-release and long-acting opioid medications1.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS116147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel